KODIAK SCIENCES INC (KOD)

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

/PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and...

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Gapping stocks in Monday's session

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the...

Kodiak Sciences to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences to Present at Innovate Retina 2024

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be...

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024

KOD stock results show that Kodiak Sciences beat analyst estimates for earnings per share the second quarter of 2024.

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the second quarter of 20...

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three...

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the first quarter of 202...

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024

KOD stock results show that Kodiak Sciences beat analyst estimates for earnings per share the first quarter of 2024.

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue...

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile....

Commit To Purchase Kodiak Sciences At $1.50, Earn 10% Using Options

KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023

KOD stock results show that Kodiak Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.

KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the fourth quarter of 20...

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection...

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Commit To Purchase Kodiak Sciences At $2.50, Earn 16% Using Options

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. "We have...